GTBP RSI Chart
Last 7 days
-6.3%
Last 30 days
-21.4%
Last 90 days
-26.9%
Trailing 12 Months
-64.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 0 | 0 | 0 | 0 |
2023 | 536.0K | 0 | 0 | 780.0K |
2022 | 5.0M | 3.5M | 1.9M | 292.0K |
2021 | 0 | 0 | 8.2M | 6.6M |
2016 | 0 | 0 | 0 | 9.8M |
2015 | 0 | 0 | 0 | 0 |
2014 | 0 | 0 | 0 | 0 |
2013 | 666.0K | 990.0K | 1.1M | 875.0K |
2012 | 0 | 131.3K | 236.7K | 342.0K |
2011 | 0 | 16.0K | 21.0K | 26.0K |
2010 | 0 | 0 | 0 | 11.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Aug 11, 2023 | breen michael martin | acquired | 57,400 | 0.287 | 200,000 | executive chairman/interim ceo |
Aug 11, 2023 | ohri manu | acquired | 57,400 | 0.287 | 200,000 | cfo & secretary |
Aug 11, 2023 | ohri manu | sold | -57,400 | 0.287 | -200,000 | cfo & secretary |
Apr 11, 2023 | breen michael martin | bought | 25,000 | 0.5 | 50,000 | executive chairman/interim ceo |
Apr 06, 2023 | ohri manu | bought | 25,000 | 0.5 | 50,000 | cfo & secretary |
Jul 15, 2022 | ohri manu | acquired | - | - | 100,000 | cfo & secretary |
Jul 15, 2022 | breen michael martin | acquired | - | - | 278,058 | exec. chair. and interim ceo |
Jul 15, 2022 | ohri manu | sold | - | - | -100,000 | cfo & secretary |
Which funds bought or sold GTBP recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | sold off | -100 | -4,948 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | sold off | -100 | -5,043 | - | -% |
May 15, 2024 | TWO SIGMA SECURITIES, LLC | sold off | -100 | -9,481 | - | -% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | sold off | -100 | -16,818 | - | -% |
May 15, 2024 | Royal Bank of Canada | sold off | -100 | - | - | -% |
May 15, 2024 | Royal Bank of Canada | new | - | - | - | -% |
May 15, 2024 | GOLDMAN SACHS GROUP INC | sold off | -100 | -5,831 | - | -% |
May 15, 2024 | CITADEL ADVISORS LLC | sold off | -100 | -14,741 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | new | - | 10,193 | 10,193 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | sold off | -100 | -273 | - | -% |
Unveiling GT Biopharma Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to GT Biopharma Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
GT Biopharma Inc. News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2016Q4 | 2016Q3 | 2016Q2 | 2016Q1 | 2015Q4 | 2015Q3 | 2015Q2 | 2015Q1 | 2014Q4 | 2014Q3 | 2013Q4 | 2013Q3 |
Revenue | -7.2% | 142,000 | 153,000 | 164,000 | - | - | - | - | - | - | - | - | 1,543,000 | 14,684,000 | 18,742,667 | 22,801,333 | 26,860,000 | 20,155,250 | 13,450,500 | 6,745,750 | 41,000 | 183,000 |
Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20,000 | 7,000 | -2,000 | -2,000 | 11,000 | 60,000 |
Operating Expenses | - | - | - | - | - | - | - | - | 52,504,500 | - | - | - | - | - | - | - | - | - | - | - | - | - |
S&GA Expenses | 27.8% | 2,314,000 | 1,811,000 | 2,015,000 | 2,936,000 | 4,280,000 | 1,875,000 | 3,355,000 | 11,874,000 | 4,946,000 | - | - | - | - | - | - | - | - | - | - | - | - |
R&D Expenses | -42.7% | 777,000 | 1,357,000 | 1,650,000 | 2,842,000 | 2,743,000 | 1,139,000 | 2,087,000 | 6,304,000 | 1,008,000 | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA Margin | -1.5% | -19.02 | -18.74 | -27.66 | -50.77 | -7.54 | -4.09 | -2.81 | -2.14 | -2.85 | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | - | - | - | 212,000 | - | - | - | - | 22,000 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Income Taxes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | - | - | - | - | - | - | - | - | - | - | -2,829,000 | -3,630,000 | 1,543,000 | 14,684,000 | -26,113,000 | -1,692,000 | 26,860,000 | -20,516,000 | -18,655,000 | -4,219,000 | - | - |
EBT Margin | 0% | -19.02 | -19.02 | -27.67 | -50.80 | -7.93 | -4.30 | -2.95 | -2.24 | -1.81 | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | 23.5% | -2,266,000 | -2,962,000 | -227,000 | -5,584,000 | -6,881,000 | -2,979,000 | -5,440,000 | -18,022,000 | -5,453,000 | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income Margin | -26.8% | -12.35 | -9.74 | -29.24 | -71.52 | -17.81 | -9.24 | -6.71 | -8.78 | -5.65 | - | - | - | - | - | - | - | - | - | - | - | - |
Free Cashflow | -100.5% | -4,200,000 | -2,095,000 | -2,906,000 | -4,298,000 | -2,918,000 | -2,786,000 | -5,215,000 | -3,705,000 | -3,929,000 | - | - | - | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Assets | -29.7% | 10.00 | 14.00 | 16.00 | 18.00 | 20.00 | 17.00 | 21.00 | 24.00 | 27.00 | 32.00 | 6.00 | 1.00 | 1.00 | 0.00 | 9.00 | 17.00 | 26.00 | 26.00 | 25.00 | 27.00 | 255 |
Current Assets | -29.7% | 10.00 | 14.00 | 16.00 | 18.00 | 20.00 | 17.00 | 21.00 | 24.00 | 27.00 | 32.00 | 6.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 |
Cash Equivalents | 80.7% | 2.00 | 1.00 | 3.00 | 3.00 | 2.00 | 6.00 | 2.00 | 5.00 | 7.00 | 9.00 | 5.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 |
Net PPE | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | -30.6% | 5.00 | 7.00 | 6.00 | 6.00 | 7.00 | 5.00 | 5.00 | 9.00 | 10.00 | 10.00 | 27.00 | 31.00 | - | 21.00 | 20.00 | 19.00 | 17.00 | 16.00 | 14.00 | 13.00 | 9.00 |
Current Liabilities | -30.6% | 5.00 | 7.00 | 5.00 | 5.00 | 4.00 | 5.00 | 5.00 | 9.00 | 10.00 | 10.00 | 35.00 | 31.00 | 29.00 | 21.00 | 20.00 | 19.00 | 17.00 | 16.00 | 14.00 | 13.00 | 9.00 |
LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | 26.00 | 23.00 | 22.00 | 13.00 | 13.00 | 13.00 | 12.00 | 11.00 | 11.00 | 11.00 | 7.00 |
Shareholder's Equity | -28.9% | 5.00 | 7.00 | 10.00 | 12.00 | 13.00 | 12.00 | 16.00 | 15.00 | 18.00 | 22.00 | - | - | - | - | - | 0.00 | 0.00 | 10.00 | 11.00 | 13.00 | 246 |
Retained Earnings | -0.3% | -684 | -682 | -679 | -676 | -674 | -674 | -668 | -662 | -659 | -653 | -595 | -589 | -586 | -569 | -567 | -565 | -535 | -533 | -528 | -524 | -288 |
Additional Paid-In Capital | 0.0% | 690 | 690 | 689 | 688 | 688 | 686 | 685 | 677 | 677 | 674 | 566 | -559 | 559 | 548 | 548 | 548 | 545 | 543 | 540 | 538 | 535 |
Shares Outstanding | 0% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | - | - | - | - | - | - | - | - | - | - |
Minority Interest | - | - | - | - | - | - | - | - | - | - | - | -0.17 | -0.17 | -0.17 | -0.17 | -0.17 | -0.17 | -0.17 | -0.17 | -0.17 | -0.17 | -0.17 |
Float | - | - | - | - | 12.00 | - | - | - | 90.00 | - | - | - | - | 9.00 | - | - | - | 7.00 | - | - | - | 40.00 |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -100.5% | -4,200 | -2,095 | -2,005 | -1,894 | -2,906 | -4,298 | -2,918 | -2,786 | -5,215 | -3,705 | -3,929 | -4,288 | -3,684 | -1,927 | -1,701 | -3,411 | -223 | -485 | -1,126 | -1,087 | -961 |
Share Based Compensation | - | - | - | - | - | - | - | - | - | - | - | - | - | 9,807 | 269 | -147 | 147 | - | -894 | 2,497 | 1,140 | 2,565 |
Cashflow From Investing | 953.1% | 5,034 | 478 | 1,845 | 2,657 | -6,989 | 7,506 | 25.00 | 1,081 | 3,533 | 2,991 | - | - | - | - | - | - | - | - | 200 | - | - |
Cashflow From Financing | - | - | - | - | - | 6,268 | -1.00 | - | - | - | - | 137 | 16,238 | 25,942 | 6,874 | 1,200 | 4,257 | 200 | 200 | 975 | 1,300 | 952 |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Revenues | ||
Operating Expenses: | ||
Research and development | 777 | 1,650 |
Selling, general and administrative (including $102 and $718 from stock compensation granted to officers, directors and employees during the three months ended March 31, 2024 and 2023, respectively) | 2,314 | 2,015 |
Loss from Operations | 3,091 | 3,665 |
Other (Income) Expense | ||
Interest income | (142) | (164) |
Interest expense | 212 | |
Change in fair value of warrant liability | (658) | (2,924) |
Gain on extinguishment of debt | (533) | |
Unrealized loss (gain) on marketable securities | 2 | (29) |
Other | (27) | |
Total Other (Income) Expense | (825) | (3,438) |
Net Loss | $ (2,266) | $ (227) |
Net Loss Per Share - Basic | $ (1.64) | $ (0.21) |
Net Loss Per Share - Diluted | $ (1.64) | $ (0.21) |
Weighted average common shares outstanding - basic | 1,380,633 | 1,082,871 |
Weighted average common shares outstanding - diluted | 1,380,633 | 1,082,871 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets | ||
Cash and cash equivalents | $ 1,950 | $ 1,079 |
Short-term investments | 7,857 | 12,893 |
Prepaid expenses and other current assets | 78 | 84 |
Total Current Assets | 9,885 | 14,056 |
Operating lease right-of-use asset | 27 | 53 |
TOTAL ASSETS | 9,912 | 14,109 |
Current liabilities | ||
Accounts payable | 3,213 | 4,328 |
Accrued expenses | 963 | 1,195 |
Current operating lease liability | 30 | 58 |
Warrant liability | 394 | 1,052 |
Total Current Liabilities | 4,600 | 6,633 |
Total Liabilities | 4,600 | 6,633 |
Stockholders’ Equity | ||
Convertible Preferred stock, par value $0.01, 15,000,000 shares authorized Series C - 96,230 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 1 | 1 |
Common stock, par value $0.001, 250,000,000 shares authorized, 1,380,633 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 1 | 1 |
Additional paid in capital | 689,641 | 689,539 |
Accumulated deficit | (684,331) | (682,065) |
Total Stockholders’ Equity | 5,312 | 7,476 |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ 9,912 | $ 14,109 |